Mark W Lowdell

Operating RegenMed: development of better in-theater strategies for handling tissue-engineered organs and tissues.

Jonathan M Fishman, Justin C R Wormald, Mark W Lowdell, 2014, Regenerative medicine.

Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy.

Heide Kogelberg, Roland Contreras, Mark W Lowdell, 2007, Glycobiology.

T-cell receptor gene-modified cells: past promises, present methodologies and future challenges.

Mark W Lowdell, Rita Tendeiro Rego, Emma C Morris, 2019, Cytotherapy.

Decellularized material as scaffolds for tissue engineering studies in long gap esophageal atresia

Paolo De Coppi, Mark W Lowdell, Luca Urbani, 2017, Expert opinion on biological therapy.

Immunomodulatory effect of a decellularized skeletal muscle scaffold in a discordant xenotransplantation model

Mark Turmaine, Paolo De Coppi, Tahera Ansari, 2013, Proceedings of the National Academy of Sciences.

Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures

A Graham Pockley, Meghavi Mashar, Mark W Lowdell, 2019, PloS one.

2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.

Mark W Lowdell, Andrew J Steele, Anastasios Chanalaris, 2009, Blood.

Stem-cell-based, tissue engineered tracheal replacement in a child: a 2-year follow-up study

Claire Crowley, Alexander M Seifalian, Paolo De Coppi, 2012, The Lancet.